Symptomatic Hyperventilation in Individuals Living With Stroke

NCT07840703 | Not Yet Recruiting

• 1 other identifier: 116
• Study Type: observational
• Target: 92
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study will investigate the effects of hyperventilation syndrome on respiratory muscle strength, respiratory muscle endurance, pulmonary functions, and functional capacity in individuals living with stroke, and in this context, stroke patients with and without hyperventilation syndrome based on Nijmegen Questionnaire scores will be compared to evaluate the relationship between symptom burden and respiratory parameters.

Conditions

Stroke; Hyperventilation Syndrome

Keywords

Stroke; Hyperventilation syndrome; Respiratory muscle strength; Respiratory muscle endurance; Pulmonary function; Functional capacity

Outcome Measures

Primary Outcomes (2)

• Change in Forced Expiratory Volume in One Second (FEV1 % predicted)

  FEV1 percent predicted values will be measured to evaluate and compare pulmonary function between the hyperventilation syndrome group and the control group.

  Measured at baseline/assessment

• Maximal inspiratory pressure (PImax)

  Maximal inspiratory pressure will be assessed to determine respiratory muscle strength.

  Measured at baseline/assessment.

Secondary Outcomes (5)

• Maximal expiratory pressure (PEmax)

  Measured at baseline/assessment.

• Respiratory Muscle Endurance Score

  Measured at baseline/assessment.

• Forced Vital Capacity (FVC)

  Measured at baseline/assessment.

• Peak Expiratory Flow (PEF)

  Measured at baseline/assessment.

• Six-Minute Walk Distance (6MWD)

  Measured at baseline/assessment.

Study Arms (2)

Hyperventilation Syndrome Group

Other: Respiratory Function, Respiratory Muscle Strength, and Functional Capacity Assessments

Without Hyperventilation Syndrome Group

Other: Respiratory Function, Respiratory Muscle Strength, and Functional Capacity Assessments

Interventions

Respiratory Function, Respiratory Muscle Strength, and Functional Capacity Assessments OTHER

Both groups will undergo comprehensive evaluations including pulmonary function tests (FEV1, FVC, PEF), respiratory muscle strength (PImax, PEmax), respiratory muscle endurance tests, the Nijmegen Questionnaire, and the six-minute walk test (6MWT) to assess functional capacity.

Hyperventilation Syndrome Group; Without Hyperventilation Syndrome Group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will comprise adult individuals diagnosed with stroke (ischaemic or haemorrhagic) who are in the post-stroke period. Participants will be recruited and screened based on the Nijmegen Questionnaire score to form two distinct cohorts: individuals presenting with symptomatic hyperventilation syndrome and individuals without hyperventilation syndrome.

You may qualify if:

• Individuals who will be diagnosed with a confirmed first-ever or recurrent stroke (ischaemic or haemorrhagic) verified by neuroimaging (CT or MRI).
• Individuals who will be in the chronic or subacute post-stroke period (medically stable following stroke onset).
• Individuals aged 18 years and older.
• Individuals who will be classified into either the hyperventilation syndrome group based on a Nijmegen Questionnaire score of ≥23 or the control group based on a score of \<23.
• Individuals who will be able to comprehend instructions and cooperate adequately with pulmonary function tests, respiratory muscle testing, and physical performance assessments.
• Individuals who will provide written informed consent to participate in the study.

You may not qualify if:

• Individuals who will present with severe cognitive impairment, aphasia, or psychiatric disorders that will prevent reliable completion of questionnaires (such as the Nijmegen Questionnaire) or cooperation with test procedures.
• Individuals who will have pre-existing primary chronic obstructive pulmonary disease (COPD), asthma, restrictive thoracic diseases, or other major pre-existing pulmonary pathologies that will confound pulmonary function test results.
• Individuals who will have unstable cardiovascular conditions (e.g., recent myocardial infarction within the past 3-6 months, unstable angina pectoris, uncontrolled malignant arrhythmias, or uncontrolled severe hypertension) that will pose a risk during physical testing (such as the six-minute walk test).
• Individuals who will have severe orthopedic, musculoskeletal, or lower extremity peripheral disorders unrelated to stroke that will independently limit functional capacity and walking distance (6MWD).
• Individuals who will have active respiratory tract infections or acute pulmonary illnesses at the time of evaluation. Individuals who will be participating in an active pulmonary rehabilitation program or receiving respiratory muscle training concurrently.

Sponsors & Collaborators

• Istinye University: lead

MeSH Terms

Conditions

Stroke

Interventions

Inhalation

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Respiratory Mechanics; Respiration; Respiratory Physiological Phenomena; Circulatory and Respiratory Physiological Phenomena

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr. Assistant Professor

Study Record Dates

• First Submitted: September 19, 2026
• First Posted: September 25, 2026
• Study Start: September 25, 2026
• Primary Completion (Estimated): December 15, 2026
• Study Completion (Estimated): December 15, 2026
• Last Updated: September 25, 2026

Record last verified: 2026-09